Skip to main content
ONCOSIL MEDICAL LTD logo

ONCOSIL MEDICAL LTD — Investor Relations & Filings

Ticker · OSL ISIN · AU000000OSL3 ASX Manufacturing
Open in API
Filings indexed 1,199 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country AU Australia
Listing ASX OSL

About ONCOSIL MEDICAL LTD

https://www.oncosil.com

OncoSil Medical Ltd is a medical technology company focused on the development and commercialization of localized treatments for patients with unresectable cancers. The company's lead product, OncoSil, is a targeted radioactive isotope microparticle therapy designed to deliver a concentrated dose of beta radiation directly into solid tumors. It is primarily indicated for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. The device utilizes Phosphorus-32 microparticles administered via endoscopic ultrasound-guided fine-needle injection, providing a localized brachytherapy approach intended to reduce tumor volume and improve surgical resectability. OncoSil Medical holds regulatory approvals in multiple jurisdictions, including the CE Mark for use in the European Union and the United Kingdom, and continues to evaluate clinical applications for other solid tumor types.

Recent filings

Filing Released Lang Actions
Key New Ethics Approval for Italian Patient Registry 3 pages 358.0KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement regarding ethics committee approval for a patient registry and procurement framework in Italy. It is not a financial report (e.g., Annual Report, Interim Report), nor does it announce dividends, capital changes, M&A, or contain detailed financial data. It is a general regulatory/compliance update and does not attach or publish a longer report. This fits best into the fallback category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2026-05-27 English
Application for quotation of securities - OSL 7 pages 20.8KB
Share Issue/Capital Change Classification · 93% confidence The document is an ASX Appendix 2A application for quotation of securities by OncoSil Medical Ltd, detailing the issuance and listing of employee incentive shares (191,667 ordinary shares) and changes to issued capital. This is a capital change/share issuance announcement, matching the Share Issue/Capital Change category.
2026-05-26 English
Notification regarding unquoted securities - OSL 7 pages 21.5KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX Appendix 3G notification detailing the issue of new unquoted equity securities (employee incentive options) and provides full issuance and capital structure details. This is a corporate disclosure of a capital change (new security issue). It fits the “Share Issue/Capital Change” category (Code: SHA), which covers announcements of new share (or option) issues and other capital structure changes.
2026-05-26 English
Appointment of Company Secretary 1 page 170.9KB
Board/Management Information Classification · 87% confidence The document is an ASX announcement titled “Appointment of Company Secretary,” detailing the appointment of a new Joint Company Secretary. This clearly represents a senior management change announcement and fits the definition of Board/Management Information (MANG).
2026-05-24 English
New Clinical Evidence for OncoSil Device Presented at ASCO 3 pages 390.8KB
Regulatory Filings Classification · 45% confidence The document is an ASX Announcement press release detailing clinical data acceptance for a poster presentation at ASCO. It contains no financial statements, management changes, capital or dividend details, or proxy materials. It is a general regulatory announcement on a material corporate development, so it falls under the fallback category “Regulatory Filings (RNS).”
2026-05-21 English
OncoSil Medical Receives TGA Approval in Australia 3 pages 380.2KB
Regulatory Filings Classification · 82% confidence The document is an ASX announcement press release stating that OncoSil Medical has received TGA approval for its medical device. It contains no financial statements, no reference to shareholder votes, no earnings or management discussion, and no executive certifications. It is a general regulatory announcement of product approval, fitting the fallback category for miscellaneous regulatory filings (RNS).
2026-05-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.